The Effects of Elinzanetant on Simulated Driving Performance in Healthy Women: A Randomized Phase I Study
Clinical and Translational Science · 2025-07 · 18 (7)
DOI: 10.1111/cts.70282 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, online erschienen am 26.06.2025. Verfasst von Klaus Francke und 4 weiteren Autor:innen. Beteiligte Einrichtung: Bayer AG, Berlin, Germany. Hauptthemen laut MEDLINE: Automobile Driving, Pyrrolidines, Neurokinin-1 Receptor Antagonists, Psychomotor Performance. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer CC AG, Basel, Switzerland.
Abstract (Originalsprache)
Elinzanetant is a dual neurokinin–1 and –3 receptor antagonist in development for treating vasomotor symptoms associated with menopause. Its central nervous system action and bedtime dosing could produce next‐morning residual effects that impact safety when driving. We therefore conducted a randomized, double‐blind, placebo‐ and active‐controlled, four‐period, crossover study to assess the effect of elinzanetant on next‐morning simulated driving performance. Sixty‐four healthy women aged 40–65 years with regular sleep patterns were randomized to receive elinzanetant 120 mg, elinzanetant 240 mg, zopiclone 7.5 mg, or placebo for 5 days in one of four sequences. The primary endpoint assessed participant's ability to maintain a consistent position within the lane, measured using standard deviation of lateral position (SDLP). Secondary assessments included lane exceedance, cornering speeds, and treatment‐emergent adverse events (TEAEs), among others. The least squares mean SDLP for both doses of elinzanetant on Day 2 and Day 6 were significantly below the non‐inferiority margin of 4.4 cm ( p < 0.0001). Small increases in SDLP with both doses versus placebo were observed on Day 2 but not on Day 6. Secondary assessments were not significantly different to placebo, apart from lane exceedances and cornering speed threshold exceedances. TEAEs were reported in 84% of participants; most were mild, and there was no increase in TEAE frequency with the 240 mg dose. Our study demonstrated no clinically relevant next‐morning residual effects following bedtime elinzanetant dosing and confirmed the elinzanetant benefit: risk balance was not adversely impacted by somnolence or fatigue the following morning. Trial Registration: ClinicalTrials.gov identifier: NCT06219902
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bayer AG, Berlin, Germany.
- Bayer US LLC, Whippany, New Jersey, USA.
- Cognitive Research Corporation, St. Petersburg, Florida, USA.
ORCID-Profile: Klaus Francke, Marcus-Hillert Schultze-Mosgau
Förderung
- Bayer CC AG, Basel, Switzerland
Zitieren
APA
Francke, K., Klein, S., Burke, J., Schultze-Mosgau, M. H., & Kay, G. (2025). The Effects of Elinzanetant on Simulated Driving Performance in Healthy Women: A Randomized Phase I Study. Clinical and Translational Science, 18(7). https://doi.org/10.1111/cts.70282
Vancouver
Francke K, Klein S, Burke J, Schultze-Mosgau MH, Kay G. The Effects of Elinzanetant on Simulated Driving Performance in Healthy Women: A Randomized Phase I Study. Clinical and Translational Science. 2025;18(7). doi:10.1111/cts.70282
BibTeX
@article{Francke2025,
author = {Francke, Klaus and Klein, Stefan and Burke, Jennifer and Schultze-Mosgau, Marcus-Hillert and Kay, Gary},
title = {The Effects of Elinzanetant on Simulated Driving Performance in Healthy Women: A Randomized Phase I Study},
journal = {Clinical and Translational Science},
year = {2025},
volume = {18},
number = {7},
doi = {10.1111/cts.70282}
}
EUVIMED